Astra strikes deal for US rival

AstraZeneca today said it would move into the vaccines market after unveiling the acquisition of US company MedImmune for more than £7bn (€10.3bn).

Astra strikes deal for US rival

AstraZeneca today said it would move into the vaccines market after unveiling the acquisition of US company MedImmune for more than £7bn (€10.3bn).

The pharmaceuticals group will pay $15.2bn (€11.2bn) for its US rival, which owns and manufactures Synagis, a leading treatment for respiratory tract infections in babies and children.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited